Agenus Inc. (NASDAQ: AGEN) reported that its experimental cancer drug combination botensilimab plus balstilimab has advanced to a phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE